If you want to compare how much more has been completed compared with the FY19 report read this:
Clinical progress
The Company is greatly encouraged by these advances, which have been pivotal in the delivery of
further intravenous infusion study safety data in small animals, indicating a wide therapeutic dose
window.
Positive kidney and urinary tract infection efficacy data indicates the potential use of RECCE® 327 across
the full therapeutic approach to the treatment of patients with sepsis.
With a compelling data package, the business is on track to formalise a clinical trial agreement to start a
first-in-human Phase I trial and, submit an application to start a topical Phase I/II trial. We look forward
to providing updates as these programs advance.
- Forums
- ASX - By Stock
- RCE
- Ann: Appendix 4D and Half Yearly Report
Ann: Appendix 4D and Half Yearly Report, page-6
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RCE (ASX) to my watchlist
|
|||||
Last
49.5¢ |
Change
0.010(2.06%) |
Mkt cap ! $114.6M |
Open | High | Low | Value | Volume |
48.5¢ | 51.0¢ | 48.5¢ | $1.909K | 3.908K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 15775 | 48.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
49.5¢ | 66869 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 15775 | 0.485 |
1 | 25000 | 0.480 |
3 | 249999 | 0.475 |
3 | 10641 | 0.470 |
1 | 12500 | 0.465 |
Price($) | Vol. | No. |
---|---|---|
0.495 | 66666 | 1 |
0.510 | 45304 | 3 |
0.515 | 1504 | 1 |
0.550 | 29407 | 2 |
0.570 | 44444 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online